| Literature DB >> 34514737 |
Rinzhin T Sherpa1, Chase Fiore1, Karni S Moshal1, Adam Wadsworth1, Michael W Rudokas1, Shailesh R Agarwal1, Robert D Harvey1.
Abstract
Compartmentation of cAMP signaling is a critical factor for maintaining the integrity of receptor-specific responses in cardiac myocytes. This phenomenon relies on various factors limiting cAMP diffusion. Our previous work in adult rat ventricular myocytes (ARVMs) indicates that PKA regulatory subunits anchored to the outer membrane of mitochondria play a key role in buffering the movement of cytosolic cAMP. PKA can be targeted to discrete subcellular locations through the interaction of both type I and type II regulatory subunits with A-kinase anchoring proteins (AKAPs). The purpose of this study is to identify which AKAPs and PKA regulatory subunit isoforms are associated with mitochondria in ARVMs. Quantitative PCR data demonstrate that mRNA for dual specific AKAP1 and 2 (D-AKAP1 & D-AKAP2), acyl-CoA-binding domain-containing 3 (ACBD3), optic atrophy 1 (OPA1) are most abundant, while Rab32, WAVE-1, and sphingosine kinase type 1 interacting protein (SPHKAP) were barely detectable. Biochemical and immunocytochemical analysis suggests that D-AKAP1, D-AKAP2, and ACBD3 are the predominant mitochondrial AKAPs exposed to the cytosolic compartment in these cells. Furthermore, we show that both type I and type II regulatory subunits of PKA are associated with mitochondria. Taken together, these data suggest that D-AKAP1, D-AKAP2, and ACBD3 may be responsible for tethering both type I and type II PKA regulatory subunits to the outer mitochondrial membrane in ARVMs. In addition to regulating PKA-dependent mitochondrial function, these AKAPs may play an important role by buffering the movement of cAMP necessary for compartmentation.Entities:
Keywords: A kinase anchoring proteins; cAMP; mitochondria; ventricular myocytes
Mesh:
Substances:
Year: 2021 PMID: 34514737 PMCID: PMC8436057 DOI: 10.14814/phy2.15015
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Information on antibodies used for biochemical studies
| Antibody | Manufacturer/Catalog number | WB dilution | IF dilution | References |
|---|---|---|---|---|
| Primary antibodies | ||||
| ACBD3 | Santa Cruz Biotech sc−101277 | 1:500 | 1:100 | Teoule et al., |
| D‐AKAP1 | MyBioSource MBS8243156 | 1:800 | 1:100 | Fernández‐Araujo et al., |
| D‐AKAP2 | Abnova H00011216‐M04 | 1:100 | Eggers et al., | |
| D‐AKAP2 | Santa Cruz Biotech sc−98755 | 1:500 | ||
| OPA1 | Santa Cruz Biotech sc−393296 | 1:500 | 1:100 | Huang et al., |
| Rab32 | Santa Cruz Biotech sc−390178 | 1:500 | Kalogeropulou et al., | |
| WAVE−1 | Santa Cruz Biotech sc−271507 | 1:500 | Moore et al., | |
| SPHKAP | Invitrogen PA5‐27581 | 1:800 | ||
| PKA RI‐α/β | Santa Cruz Biotech sc−271125 | 1:500 | 1:50 | Chen et al., |
| PKA RII‐α | Santa Cruz Biotech sc−137220 | 1:500 | 1:50 | Muñoz‐Llancao et al., |
| PKA RII‐β | Santa Cruz Biotech sc−376778 | 1:500 | 1:50 | Just‐Borràs et al., |
| PKA Cat‐α/β/γ | Santa Cruz Biotech sc−365615 | 1:500 | Tibenska et al., | |
| TOMM20 | Cell Signaling Technology 42406 | 1:1000 | 1:100 | Nie et al., |
| TOMM20 | Abcam ab56783 | 1:100 | Casey et al., | |
| SERCA2 | Invitrogen MA3‐919 | 1:1000 | Rudokas et al., | |
| Na,K‐ATPase α1 | Cell Signaling Technology 3010S | 1:1000 | Lou et al., | |
| Tubulin | Sigma Aldrich T5168 | 1:15000 | ||
| Secondary antibodies | ||||
| Goat anti‐mouse Alexa Fluor 568 | Invitrogen A11004 | 1:1000 | ||
| Goat anti‐rabbit Alexa Fluor 647 | Invitrogen A32733 | 1:1000 | ||
| Peroxidase‐AffiniPure Goat Anti‐Mouse IgG |
Jackson ImmunoResearch 115–035–003 | 1:5000 | ||
| Peroxidase AffiniPure Goat Anti‐Rabbit IgG |
Jackson ImmunoResearch 111–035–003 | 1:5000 | ||
FIGURE 1mRNA expression of mitochondria‐associated AKAPs in ARVM. Bar graphs show the mean ± S.E.M. expression value of AKAPs from ARVM normalized to the expression of the endogenous housekeeping gene, GAPDH; n = 7 independent RNA extractions analyzed in triplicate for each extraction
FIGURE 2Expression levels of mitochondria‐associated AKAPs in ARVM. (a) Ponceau S (Pon‐S) staining as a loading control. Lanes represent total cell lysate (T), the cytosolic fraction (C), and the mitochondria enriched fraction (M) from ARVMs. (b) Tubulin was used as a marker for the cytosolic fraction and TOMM20 as the specific mitochondrial marker. (c) PVDF membrane was probed for indicated AKAPs. Molecular weight markers are placed adjacent to the blots. n ≥ 3 independent extractions
FIGURE 3Co‐localization of D‐AKAP1 and mitochondria in ARVM. Representative confocal images of ARVM showing mitochondrial marker (a) TOMM20 and (b) D‐AKAP1. (c) Merged image of TOMM20 (red), D‐AKAP1 (green), and DAPI (blue) shows that D‐AKAP1 overlaps the mitochondrial marker. PCC = 0.77 ± 0.03; N = 4 independent isolations with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar
FIGURE 4Co‐localization of D‐AKAP2 and mitochondria in ARVM. Confocal images of ARVM showing mitochondrial marker (a) TOMM20 and (b) D‐AKAP2, presenting a punctate pattern and overlap with mitochondria. (c) Merged images representing TOMM20 (red), D‐AKAP2 (green), and DAPI (blue). PCC = 0.72 ± 0.03; N = 4 independent isolations with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar
FIGURE 5Co‐ labeling of ACBD3 with mitochondria in ARVM. Labeling of the mitochondrial marker, (a) TOMM20 and (b) ACBD3 show a similar pattern of immunoreactivity. (c) Merged images of TOMM20 (red), ACBD3 (green), and DAPI (blue) show that ACBD3 is distributed in a diffuse manner generating a PCC of 0.56 ± 0.02; N = 4 independent isolations with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar
FIGURE 6Co‐ labeling of OPA1 with mitochondria in ARVM. Labeling of the mitochondrial marker, (a) TOMM20 and (b) OPA1. (c) Merged images of TOMM20 (red), OPA1 (green), and DAPI (blue). PCC = 0.58 ± 0.03; N = 4 independent isolations with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar
FIGURE 7Expression levels of PKA subunits in mitochondria. Exemplar immunoblot for the expression of PKA regulatory, RIα/β, RIIα, RIIβ, and catalytic (Cat‐α/β/γ) subunits are shown in total cell lysate (T), the cytosolic fraction (C), and mitochondria enriched fraction (M); n ≥ 3 independent protein extractions
FIGURE 8PKA RI subunit and mitochondria co‐labeling. Representative confocal images of ARVM showing mitochondrial marker (a) TOMM20 and (b) PKA RI regulatory subunit. (c) Composite image showing strong overlap of TOMM20 (red) and PKA RI subunit (green) in the subsarcolemmal mitochondria. PKA RI antibody is also seen to label transverse striations. PCC = 0.69 ± 0.02, MOC = 0.80 ± 0.03; N = 4 independent isolations with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar
FIGURE 9Co‐localization of PKA RIIα subunit with mitochondria. Representative confocal images of ARVM showing mitochondrial marker (a) TOMM20 and (b) PKA RII‐α subunit. (c) Merged images of TOMM20 (red), PKA RIIα subunit (green), and DAPI (blue). PCC = 0.63 ± 0.02, MOC = 0.80 ± 0.02; N = 4 independent isolations with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar
FIGURE 10Co‐localization of PKA RIIβ subunit with mitochondria. Representative confocal images of ARVM showing mitochondrial marker (a) TOMM20 and (b) PKA RII‐β subunit. (c) Merged image shows moderate colocalization between TOMM20 (red), PKA RII‐β (green), and DAPI (blue). PCC = 0.61 ± 0.02, MOC = 0.73 ± 0.02; N = 4 independent isolations/experiments with n = 6 from each isolation. Magnified images are shown below each corresponding image with the appropriate scale bar